CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Syntara Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Syntara Ltd
20 Rodborough Rd
Phone: +61 294547200p:+61 294547200 FRENCHS FOREST, NSW  2086  Australia Ticker: SNTSNT

Business Summary
Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Kathleen M.Metters 66 10/3/2023 6/7/2017
Chief Executive Officer, Managing Director, Executive Director Gary J.Phillips 60 3/12/2013 12/1/2003
Chief Financial Officer, Company Secretary David M.Mcgarvey 65 12/1/2002 12/1/2002
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Pharmaxis Ltd
Pharmaxis Ltd.
PXS
5 additional Business Names available in full report.

General Information
Number of Employees: 107 (As of 6/30/2014)
Outstanding Shares: 831,006,340 (As of 12/31/2023)
Shareholders: 4,625
Stock Exchange: ASX
Fax Number: +61 294513622


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024